Economic Burden of Treatment-Resistant Depression among Adults with Chronic Non-Cancer Pain Conditions and Major Depressive Disorder in the US

被引:15
|
作者
Shah, Drishti [1 ]
Allen, Lindsay [2 ]
Zheng, Wanhong [3 ]
Madhavan, Suresh S. [1 ,4 ]
Wei, Wenhui [1 ,5 ]
LeMasters, Traci J. [1 ]
Sambamoorthi, Usha [1 ,4 ]
机构
[1] West Virginia Univ, Sch Pharm, Dept Pharmaceut Syst & Policy, POB 9510, Morgantown, WV 26506 USA
[2] West Virginia Univ, Sch Publ Hlth, Hlth Policy Management & Leadership Dept, Morgantown, WV 26506 USA
[3] West Virginia Univ, Dept Behav Med & Psychiat, Morgantown, WV 26506 USA
[4] Univ North Texas, Hlth Sci Ctr, Coll Pharm, Dept Pharmacotherapy, Ft Worth, TX USA
[5] Regeneron Pharmaceut, Tarrytown, NY USA
关键词
HEALTH-CARE EXPENDITURES; ANTIDEPRESSANT TREATMENT; TREATMENT RESPONSE; OUTCOMES; IMPACT; COSTS; POLYPHARMACY; PREVALENCE; DISABILITY; RISK;
D O I
10.1007/s40273-021-01029-2
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objective Major depressive disorder (MDD) and chronic non-cancer pain conditions (CNPC) often co-occur and exacerbate one another. Treatment-resistant depression (TRD) in adults with CNPC can amplify the economic burden. This study examined the impact of TRD on direct total and MDD-related healthcare resource utilization (HRU) and costs among commercially insured patients with CNPC and MDD in the US. Methods The retrospective longitudinal cohort study employed a claims-based algorithm to identify adults with TRD from a US claims database (January 2007 to June 2017). Costs (2018 US$) and HRU were compared between patients with and without TRD over a 12-month period after TRD/non-TRD index date. Counterfactual recycled predictions from generalized linear models were used to examine associations between TRD and annual HRU and costs. Post-regression linear decomposition identified differences in patient-level factors between TRD and non-TRD groups that contributed to the excess economic burden of TRD. Results Of the 21,180 adults with CNPC and MDD, 10.1% were identified as having TRD. TRD patients had significantly higher HRU, translating into higher average total costs (US$21,015(TRD) vs US$14,712(No TRD)) and MDD-related costs (US$1201(TRD) vs US$471(No TRD)) compared with non-TRD patients (all p < 0.001). Prescription drug costs accounted for 37.6% and inpatient services for 30.7% of the excess total healthcare costs among TRD patients. TRD patients had a significantly higher number of inpatient (incidence rate ratio [IRR] 1.30, 95% CI 1.14-1.47) and emergency room visits (IRR 1.21, 95% CI 1.10-1.34) than non-TRD patients. Overall, 46% of the excess total costs were explained by differences in patient-level characteristics such as polypharmacy, number of CNPC, anxiety, sleep, and substance use disorders between the TRD and non-TRD groups. Conclusion TRD poses a substantial direct economic burden for adults with CNPC and MDD. Excess healthcare costs may potentially be reduced by providing timely interventions for several modifiable risk factors.
引用
收藏
页码:639 / 651
页数:13
相关论文
共 50 条
  • [1] Economic Burden of Treatment-Resistant Depression among Adults with Chronic Non-Cancer Pain Conditions and Major Depressive Disorder in the US
    Drishti Shah
    Lindsay Allen
    Wanhong Zheng
    Suresh S. Madhavan
    Wenhui Wei
    Traci J. LeMasters
    Usha Sambamoorthi
    PharmacoEconomics, 2021, 39 : 639 - 651
  • [2] ECONOMIC BURDEN OF TREATMENT-RESISTANT DEPRESSION AMONG ADULTS WITH CHRONIC NON-CANCER PAIN CONDITIONS AND MAJOR DEPRESSIVE DISORDER
    Shah, D.
    Zheng, W.
    Allen, L.
    Wei, W.
    Madhavan, S.
    LeMasters, T.
    Sambamoorthi, U.
    VALUE IN HEALTH, 2020, 23 : S201 - S201
  • [3] Using a machine learning approach to investigate factors associated with treatment-resistant depression among adults with chronic non-cancer pain conditions and major depressive disorder
    Shah, Drishti
    Zheng, Wanhong
    Allen, Lindsay
    Wei, Wenhui
    LeMasters, Traci
    Madhavan, Suresh
    Sambamoorthi, Usha
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (05) : 847 - 859
  • [4] PREDICTORS OF TREATMENT RESISTANT DEPRESSION AMONG ADULTS WITH CHRONIC NON-CANCER PAIN CONDITIONS: A MACHINE LEARNING APPROACH
    Shah, D.
    Zheng, W.
    Allen, L.
    Wei, W.
    Suresh, M.
    LeMasters, T. J.
    Sambamoorthi, U.
    VALUE IN HEALTH, 2019, 22 : S226 - S226
  • [5] The Prevalence and National Burden of Treatment-Resistant Depression and Major Depressive Disorder in the United States
    Zhdanava, Maryia
    Pilon, Dominic
    Ghelerter, Isabelle
    Chow, Wing
    Joshi, Kruti
    Lefebvre, Patrick
    Sheehan, John J.
    JOURNAL OF CLINICAL PSYCHIATRY, 2021, 82 (02)
  • [6] Economic Burden of Treatment-Resistant Depression in Privately Insured US Patients with Physical Conditions
    Zhdanava, Maryia
    Kuvadia, Harsh
    Joshi, Kruti
    Daly, Ella
    Pilon, Dominic
    Rossi, Carmine
    Morrison, Laura
    Lefebvre, Patrick
    Nelson, Craig
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (08): : 996 - +
  • [7] QUANTIFYING THE REAL-WORLD ECONOMIC BURDEN OF MAJOR DEPRESSIVE DISORDER AND TREATMENT-RESISTANT DEPRESSION IN ENGLAND: NATIONAL AND REGIONAL ESTIMATES
    Kailey, R.
    Safinia, L.
    Denee, T.
    Wood, R.
    Tritton, T.
    Massey, O.
    VALUE IN HEALTH, 2020, 23 : S585 - S586
  • [8] Transformative Therapies for Depression: Postpartum Depression, Major Depressive Disorder, and Treatment-Resistant Depression
    Richardson, Elizabeth
    Patterson, Riah
    Meltzer-Brody, Samantha
    Mcclure, Robert
    Tow, Amanda
    ANNUAL REVIEW OF MEDICINE, 2025, 76 : 81 - 93
  • [9] Economic Burden of Treatment-Resistant Depression on the US Health Care System
    Sussman, Matthew
    O'Sullivan, Amy K.
    Shah, Ankit
    Olfson, Mark
    Menzin, Joseph
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2019, 25 (07): : 823 - 835
  • [10] Medication treatment for depression and reduced productivity among adults with major depressive disorder in the US
    Amill-Rosario, Alejandro
    Fincannon, Alexandra
    Slejko, Julia F.
    dosReis, Susan
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 229 - 230